148 related articles for article (PubMed ID: 19729976)
21. Phase II study of oral S-1 with irinotecan and bevacizumab (SIRB) as first-line therapy for patients with metastatic colorectal cancer.
Yamada Y; Yamaguchi T; Matsumoto H; Ichikawa Y; Goto A; Kato K; Hamaguchi T; Shimada Y
Invest New Drugs; 2012 Aug; 30(4):1690-6. PubMed ID: 21894500
[TBL] [Abstract][Full Text] [Related]
22. A phase II study evaluating the feasibility of a 5-week cycle of S-1 plus irinotecan (IRIS) in patients with advanced and recurrent colorectal cancer.
Hata T; Fukunaga M; Murata K; Uemura Y; Fukuzaki T; Ota H; Ohue M; Ohnishi T; Tanaka N; Takemasa I; Mizushima T; Ikeda M; Yamamoto H; Sekimoto M; Nezu R; Doki Y; Mori M
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1657-63. PubMed ID: 23543294
[TBL] [Abstract][Full Text] [Related]
23. Dosage escalation study of S-1 and irinotecan in metronomic chemotherapy against advanced colorectal cancer.
Ogata Y; Sasatomi T; Akagi Y; Ishibashi N; Mori S; Shirouzu K
Kurume Med J; 2009; 56(1-2):1-7. PubMed ID: 20103995
[TBL] [Abstract][Full Text] [Related]
24. [Irinotecan combined with fluoropyrimidine in treatment for advanced/metastatic colorectal carcinoma].
Yu BM; Wu WQ
Zhonghua Wai Ke Za Zhi; 2005 May; 43(9):557-60. PubMed ID: 15938923
[TBL] [Abstract][Full Text] [Related]
25. Phase II study of combination therapy with S-1 and irinotecan for advanced non-small cell lung cancer: west Japan thoracic oncology group 3505.
Okamoto I; Nishimura T; Miyazaki M; Yoshioka H; Kubo A; Takeda K; Ebi N; Sugawara S; Katakami N; Fukuoka M; Nakagawa K
Clin Cancer Res; 2008 Aug; 14(16):5250-4. PubMed ID: 18698044
[TBL] [Abstract][Full Text] [Related]
26. Phase 1/2 clinical study of irinotecan and oral S-1 (IRIS) in patients with advanced gastric cancer.
Komatsu Y; Yuki S; Fuse N; Kato T; Miyagishima T; Kudo M; Kunieda Y; Tateyama M; Wakahama O; Meguro T; Sakata Y; Asaka M
Adv Ther; 2010 Jul; 27(7):483-92. PubMed ID: 20559897
[TBL] [Abstract][Full Text] [Related]
27. Phase I study of bevacizumab combined with irinotecan and S-1 as second-line chemotherapy in patients with advanced colorectal cancer.
Kusaba H; Esaki T; Kishimoto J; Uchino K; Arita S; Kumagai H; Mitsugi K; Akashi K; Baba E
Cancer Chemother Pharmacol; 2013 Jan; 71(1):29-34. PubMed ID: 23228984
[TBL] [Abstract][Full Text] [Related]
28. Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study.
Lim DH; Park YS; Park BB; Ji SH; Lee J; Park KW; Kang JH; Lee SH; Park JO; Kim K; Kim WS; Jung CW; Im YH; Kang WK; Park K
Cancer Chemother Pharmacol; 2005 Jul; 56(1):10-4. PubMed ID: 15782313
[TBL] [Abstract][Full Text] [Related]
29. Phase II study of irinotecan plus S-1 combination for previously untreated advanced non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0601.
Akie K; Oizumi S; Ogura S; Shinagawa N; Kikuchi E; Fukumoto S; Harada M; Kinoshita I; Kojima T; Harada T; Fujita Y; Ohsaki Y; Dosaka-Akita H; Isobe H; Nishimura M;
Oncology; 2011; 81(2):84-90. PubMed ID: 21968255
[TBL] [Abstract][Full Text] [Related]
30. Randomized phase II trial of S-1 plus irinotecan versus S-1 plus paclitaxel as first-line treatment for advanced gastric cancer (OGSG0402).
Sugimoto N; Fujitani K; Imamura H; Uedo N; Iijima S; Imano M; Shimokawa T; Kurokawa Y; Furukawa H; Goto M
Anticancer Res; 2014 Feb; 34(2):851-7. PubMed ID: 24511022
[TBL] [Abstract][Full Text] [Related]
31. Modified CAPOX (capecitabine plus oxaliplatin) regimen every two weeks as second-line treatment in patients with advanced colorectal cancer previously treated with irinotecan-based frontline therapy: a multicenter phase II study.
Kakolyris S; Souglakos J; Polyzos A; Ardavanis A; Ziras N; Athanasiadis A; Varthalitis I; Amarantidis K; Tsousis S; Vamvakas L; Vardakis N; Georgoulias V;
Oncology; 2008; 74(1-2):31-6. PubMed ID: 18544957
[TBL] [Abstract][Full Text] [Related]
32. A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer.
Kim GM; Jeung HC; Rha SY; Kim HS; Jung I; Nam BH; Lee KH; Chung HC
Eur J Cancer; 2012 Mar; 48(4):518-26. PubMed ID: 22243774
[TBL] [Abstract][Full Text] [Related]
33. [Irinotecan plus oral S-1 in patients with advanced colorectal cancer--biweekly IRIS regimen].
Komatsu Y; Yuki S; Tateyama M; Kudo M; Asaka M
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():131-4. PubMed ID: 16897988
[TBL] [Abstract][Full Text] [Related]
34. Phase II study of combined chemotherapy with irinotecan and S-1 (IRIS) plus bevacizumab in patients with inoperable recurrent or advanced colorectal cancer.
Komatsu Y; Yuki S; Sogabe S; Fukushima H; Nakatsumi H; Kobayashi Y; Iwanaga I; Nakamura M; Hatanaka K; Miyagishima T; Kudo M; Munakata M; Meguro T; Tateyama M; Sakata Y
Acta Oncol; 2012 Sep; 51(7):867-72. PubMed ID: 22554343
[TBL] [Abstract][Full Text] [Related]
35. Irinotecan plus capecitabine as first-line chemotherapy in advanced colorectal cancer.
Gennatas C; Michalaki V; Gennatas S; Papalambros E
Anticancer Res; 2008; 28(3B):1923-6. PubMed ID: 18630482
[TBL] [Abstract][Full Text] [Related]
36. A feasibility study of UFT/LV and irinotecan (TEGAFIRI) in advanced or metastatic colorectal cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG) PROG 0304.
Ishida H; Miyake Y; Fukunaga M; Watanabe Y; Kato T; Takemoto H; Furukawa H
Jpn J Clin Oncol; 2009 Sep; 39(9):601-5. PubMed ID: 19535386
[TBL] [Abstract][Full Text] [Related]
37. Second-line combination chemotherapy of oral S-1 with cisplatin and irinotecan for colorectal cancer resistant to 5-FU.
Tsutsumi S; Yamaguchi S; Ide M; Tsuboi K; Fukasawa T; Yamaki S; Asao T; Kuwano H
Hepatogastroenterology; 2006; 53(68):196-200. PubMed ID: 16608023
[TBL] [Abstract][Full Text] [Related]
38. Current status of capecitabine in the treatment of colorectal cancer.
Rothenberg ML
Oncology (Williston Park); 2002 Dec; 16(12 Suppl No 14):16-22. PubMed ID: 12520635
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of irinotecan plus S-1 (IRIS) therapy to treat advanced/recurrent colorectal cancer.
Higashi D; Egawa Y; Hirano Y; Hirano K; Miyake T; Takahashi H; Uwatoko S; Abe S; Yamamoto S; Mikami K; Futami K; Maekawa T; Inoue R; Miyazaki M
Anticancer Res; 2014 Aug; 34(8):4595-9. PubMed ID: 25075105
[TBL] [Abstract][Full Text] [Related]
40. A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer.
Rea DW; Nortier JW; Ten Bokkel Huinink WW; Falk S; Richel DJ; Maughan T; Groenewegen G; Smit JM; Steven N; Bakker JM; Semiond D; Kerr DJ; Punt CJ
Ann Oncol; 2005 Jul; 16(7):1123-32. PubMed ID: 15939714
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
